Page last updated: 2024-08-21

pyrazines and hydroxyurea

pyrazines has been researched along with hydroxyurea in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (10.00)29.6817
2010's2 (20.00)24.3611
2020's7 (70.00)2.80

Authors

AuthorsStudies
Chen, W; Hai, T; Mora-Jensen, H; Perez-Galan, P; Ron, D; Trenkle, W; Wang, Q; Weniger, MA; Wiestner, A; Wolford, C; Ye, Y1
Brem, GJ; Brüning, A; Mylonas, I1
Abboud, MR; Achebe, MM; Alkindi, S; Ataga, KI; Brown, RC; Diuguid, DL; El-Beshlawy, A; Elghandour, A; Gordeuk, VR; Hassab, H; Hoppe, CC; Howard, J; Intondi, A; Kanter, J; Lehrer-Graiwer, J; Nduba, V; Telfer, P; Tonda, M; Tong, B; Tsitsikas, DA; Vichinsky, E; Ware, RE1
Steinberg, MH1
Herity, LB; Lowe, DK; Rodriguez, LR; Vaughan, DM1
Ataga, KI; Brugnara, C; Staffa, SJ; Stocker, JW1
Ballas, SK; Gordeuk, VR; Hankins, JS; Kuypers, FA; Thompson, AA; Vichinsky, E1
Çanak, B; Eşkazan, AE1
Anderson, AR; Fuqua, T; Muschick, K; Stoker-Postier, C1
Fasipe, TA; Kavanagh, PL; Wun, T1

Reviews

2 review(s) available for pyrazines and hydroxyurea

ArticleYear
Voxelotor: A Novel Treatment for Sickle Cell Disease.
    The Annals of pharmacotherapy, 2021, Volume: 55, Issue:2

    Topics: Anemia, Sickle Cell; Benzaldehydes; Female; Hematologic Agents; Hemoglobins; Humans; Hydroxyurea; Male; Pyrazines; Pyrazoles; Treatment Outcome; Young Adult

2021
Sickle Cell Disease: A Review.
    JAMA, 2022, 07-05, Volume: 328, Issue:1

    Topics: Adult; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Antisickling Agents; Benzaldehydes; Child; Glutamine; Hematologic Agents; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Infant, Newborn; Neonatal Screening; Pain; Pyrazines; Pyrazoles; Transition to Adult Care; United States

2022

Trials

1 trial(s) available for pyrazines and hydroxyurea

ArticleYear
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
    The New England journal of medicine, 2019, 08-08, Volume: 381, Issue:6

    Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Biomarkers; Child; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hemoglobin, Sickle; Hemoglobins; Hemolysis; Humans; Hydroxyurea; Intention to Treat Analysis; Male; Middle Aged; Polymerization; Pyrazines; Pyrazoles; Young Adult

2019

Other Studies

7 other study(ies) available for pyrazines and hydroxyurea

ArticleYear
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells.
    Proceedings of the National Academy of Sciences of the United States of America, 2009, Feb-17, Volume: 106, Issue:7

    Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Endoplasmic Reticulum; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Hydrazones; Hydroxyurea; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Transcription, Genetic; Ubiquitin

2009
Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting ER stress and CHOP expression.
    Gynecologic oncology, 2013, Volume: 128, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Synergism; Endoplasmic Reticulum Stress; Female; HeLa Cells; Humans; Hydrazones; Hydroxyurea; Membrane Potential, Mitochondrial; Pyrazines; Transcription Factor CHOP; Ubiquitin; Up-Regulation; Uterine Cervical Neoplasms

2013
Treating sickle cell anemia: A new era dawns.
    American journal of hematology, 2020, Volume: 95, Issue:4

    Topics: Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Benzaldehydes; Child; Fetal Hemoglobin; Forecasting; Gene Expression Regulation; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Hypoxia, Brain; Infant; P-Selectin; Pain; Pyrazines; Pyrazoles; Therapies, Investigational

2020
Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial.
    British journal of haematology, 2021, Volume: 192, Issue:5

    Topics: Acetamides; Anemia, Sickle Cell; Benzaldehydes; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hemoglobins; Hemolysis; Humans; Hydroxyurea; Intermediate-Conductance Calcium-Activated Potassium Channels; Pyrazines; Pyrazoles; Trityl Compounds

2021
Time to rethink haemoglobin threshold guidelines in sickle cell disease.
    British journal of haematology, 2021, Volume: 195, Issue:4

    Topics: Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Blood Transfusion; Blood Viscosity; Genetic Therapy; Hematocrit; Hematopoietic Stem Cell Transplantation; Hemoglobin, Sickle; Hemoglobins; Humans; Hydroxyurea; Practice Guidelines as Topic; Pyrazines; Pyrazoles

2021
Spotlight Commentary - Voxelotor: A new kid on the block in the treatment of sickle cell disease.
    British journal of clinical pharmacology, 2022, Volume: 88, Issue:6

    Topics: Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Humans; Hydroxyurea; Pyrazines; Pyrazoles

2022
Real-world data on voxelotor to treat patients with sickle cell disease.
    European journal of haematology, 2022, Volume: 109, Issue:2

    Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Benzaldehydes; Bilirubin; Child; Female; Humans; Hydroxyurea; Male; Middle Aged; Pyrazines; Pyrazoles; Retrospective Studies; Young Adult

2022